Stabilizes microtubules via tubulin binding, particularly in tauopathy models.
Reference facts
- Also known as
- NAP, AL-108, NAPVSIPQ
- Category
- Nootropic & Cognitive
- Mechanism of action
- Stabilizes microtubules via tubulin binding, particularly in tauopathy models.
- Targets
- Tubulin / microtubules
- Indications under research or approved
- Phase 2/3 in progressive supranuclear palsy (failed primary endpoint 2014); ongoing research in ADNP syndrome
- Regulatory status (reference entry)
- Investigational
- Half-life
- Minutes (intranasal)
- Sequence
- NAPVSIPQ
- Sequence notes
- Octapeptide active fragment of activity-dependent neuroprotective protein (ADNP).
- Molecular weight (Da)
- 825
- Originator / sponsor
- Originally Allon Therapeutics
- First reported
- 1999
Primary References
Explore research articles about Davunetide
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.